respiratory

Two bacterial therapies show promise against COPD exacerbations: ERS 2021

Two experimental bacteria-based vaccines with very different modes of action have sparked excitement at this year’s ERS Congress, with both showing strong promise in reducing COPD exacerbations despite mixed clinical trial results. The performance of the mucosal bacterial vaccine MV130 was described by one expert as being “so impressive” it was almost “too good to ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic